| SC 13D/A | 2024-02-22 | Syncona Portfolio Ltd | Freeline Therapeutics Holdings plc | 65,872,764 | 100.0% | EDGAR |
| SC 13G/A | 2024-02-14 | EVENTIDE ASSET MANAGEMENT, LLC | Freeline Therapeutics Holdings plc | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-12 | INTEGRATED CORE STRATEGIES (US) LLC | Freeline Therapeutics Holdings plc | - | 0.0% | EDGAR |
| SC 13G/A | 2024-01-31 | Tetragon Financial Management LP | Freeline Therapeutics Holdings plc | 6,375,000 | 9.8% | EDGAR |
| SC 13D/A | 2023-11-24 | Syncona Portfolio Ltd | Freeline Therapeutics Holdings plc | 37,862,132 | 57.9% | EDGAR |
| SC 13D/A | 2023-10-18 | Syncona Portfolio Ltd | Freeline Therapeutics Holdings plc | 37,862,132 | 57.9% | EDGAR |
| SC 13G | 2023-07-17 | INTEGRATED CORE STRATEGIES (US) LLC | Freeline Therapeutics Holdings plc | 5,555,085 | 8.5% | EDGAR |
| SC 13G/A | 2023-02-14 | EVENTIDE ASSET MANAGEMENT, LLC | Freeline Therapeutics Holdings plc | 5,920,765 | 9.1% | EDGAR |
| SC 13G/A | 2023-02-13 | CHI Advisors LLC | Freeline Therapeutics Holdings plc | 4,814,419 | 7.4% | EDGAR |
| SC 13G/A | 2023-01-31 | Tetragon Financial Management LP | Freeline Therapeutics Holdings plc | 4,000,000 | 6.2% | EDGAR |
| SC 13D | 2022-03-25 | Syncona Portfolio Ltd | Freeline Therapeutics Holdings plc | 37,862,147 | 62.3% | EDGAR |
| SC 13G | 2022-03-21 | Tetragon Financial Management LP | Freeline Therapeutics Holdings plc | 3,700,000 | 6.1% | EDGAR |
| SC 13G/A | 2022-02-14 | EVENTIDE ASSET MANAGEMENT, LLC | Freeline Therapeutics Holdings plc | 3,485,656 | 9.7% | EDGAR |
| SC 13G/A | 2022-02-11 | Syncona Portfolio Ltd | Freeline Therapeutics Holdings plc | 18,814,527 | 52.5% | EDGAR |
| SC 13G | 2022-02-11 | CHI Advisors LLC | Freeline Therapeutics Holdings plc | 1,876,389 | 5.2% | EDGAR |
| SC 13G/A | 2022-02-04 | WELLINGTON MANAGEMENT GROUP LLP | Freeline Therapeutics Holdings plc | 439,795 | 1.2% | EDGAR |
| SC 13G/A | 2021-11-02 | Novo Holdings A/S | Freeline Therapeutics Holdings plc | 1,785,563 | 5.0% | EDGAR |
| SC 13G/A | 2021-08-10 | WELLINGTON MANAGEMENT GROUP LLP | Freeline Therapeutics Holdings plc | 1,813,984 | 5.1% | EDGAR |
| SC 13G | 2021-02-12 | Syncona Portfolio Ltd | Freeline Therapeutics Holdings plc | 18,814,527 | 54.2% | EDGAR |
| SC 13G | 2021-02-12 | EVENTIDE ASSET MANAGEMENT, LLC | Freeline Therapeutics Holdings plc | 2,485,656 | 7.5% | EDGAR |